Why this chain matters

Sanofi (SNYNF) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when SNYNF performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to SNYNF's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • DBV TECHNOLOGIES (DBVTF) - confidence 95%.
  • Novavax, Inc. (NVAX) - confidence 92%.
  • MacroGenics, Inc. (MGNX) - confidence 85%.
  • Arrowhead Pharmaceuticals, Inc. (ARWR) - confidence 85%.
  • Recursion Pharmaceuticals, Inc. (RXRX) - confidence 85%.
  • DBV Technologies S.A. (DBVT) - confidence 72%.
  • Nuvation Bio Inc. (NUVB) - confidence 72%.
  • Cytokinetics, Incorporated (CYTK) - confidence 72%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • BioLineRx Ltd. (BLRX) - confidence 72%.
  • Compugen Ltd. (CGEN) - confidence 72%.
  • CytomX Therapeutics, Inc. (CTMX) - confidence 72%.
  • Dianthus Therapeutics, Inc. (DNTH) - confidence 72%.
  • Editas Medicine, Inc. (EDIT) - confidence 72%.
  • Equillium, Inc. (EQ) - confidence 72%.
  • MacroGenics, Inc. (MGNX) - confidence 72%.
  • Metagenomi Therapeutics, Inc. (MGX) - confidence 72%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • DBV TECHNOLOGIES: Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciproc
  • Novavax, Inc.: Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX graph: than all of the outstanding 2031 Notes unless at least $ million aggregate principal amount of 2031 Notes are outstanding and not called
  • Arrowhead Pharmaceuticals, Inc.: Reciprocal relationship from ARWR graph: nded September 30, 2025. RESULTS OF OPERATIONS The following data summarizes the Company’s results of operations for the following periods indicated: Three Months Ended March 31, Six Months Ended March 31, 2026 2025 202
  • MacroGenics, Inc.: Reciprocal relationship from MGNX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGNX graph: IELD in November 2022, and the Company recognized $ million in revenue related to this regulatory milestone during the year ended Decemb
  • Recursion Pharmaceuticals, Inc.: Reciprocal relationship from RXRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RXRX graph: mercial success depends upon our ability, and the abi

Who benefits and who is exposed

If Sanofi outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If SNYNF struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.